Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multi

Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in  Relapsed/Refractory Mult

Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysi

Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript

Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström M

FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a l

Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism

Cellectar Biosciences Inc (NASDAQ:CLRB) shares are down during Wednesday's premarket session after t

US stocks rise, Nasdaq gains 1%. Dow up 0.57%, Nasdaq up 1.03%, S&P 500 up 0.84%. Materials up 2

Cellectar Biosciences, Inc. (NASDAQ:CLRB) shares are up during Tuesday's trading session as the comp

83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response o

Oversubscribed Financing Led by Nantahala Capital with Participation from Balyasny Asset Management,

Study will evaluate tumor-specific uptake, safety, tolerability, and preliminary efficacy signals of

Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript

On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Ag

FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a

Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Techn

Following Guidance from the European Medicines Agency's (EMA) Scientific Advice Working Party (SAWP)

Cellectar Biosciences (NASDAQ: CLRB - Get Free Report) and Perrigo (NYSE: PRGO - Get Free Report) ar

Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid Tumors